Amorphous powders for inhalation drug delivery

Advanced Drug Delivery Reviews

Volumn 100, Issue , 2016, Pages 102-115

  Chen, Lan ^a   Okuda, Tomoyuki ^b,c   Lu, Xiang Yun ^a   Chan, Hak Kim ^c  

^a UNIVERSITY OF SHANGHAI FOR SCIENCE AND TECHNOLOGY   (China)

^b MEIJO UNIVERSITY   (Japan)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aerodynamic diameter; Amorphous; Dry powder inhaler; Excipient; Solubility; Spray drying; Stability

Indexed keywords

AMORPHOUS MATERIALS; BIOCHEMISTRY; CONVERGENCE OF NUMERICAL METHODS; POWDERS; SOLUBILITY; SPRAY DRYING;

ACTIVE PHARMACEUTICAL INGREDIENTS; AERODYNAMIC DIAMETERS; BIOCHEMICAL STABILITY; DRY POWDER INHALER; EXCIPIENT; PHYSICO-CHEMICAL STABILITY; POORLY SOLUBLE DRUGS; PRODUCTION METHODS;

AERODYNAMIC STABILITY;

AMBROXOL; BIOLOGICAL PRODUCT; BOVINE SERUM ALBUMIN; BRONCHODILATING AGENT; BUDESONIDE; CHITOSAN; CIPROFLOXACIN; CLARITHROMYCIN; CLOTRIMAZOLE; COLISTIN; CYCLOSPORIN A; LACTOSE; LEUCINE; LEVOFLOXACIN; MANNITOL; METHIONINE; PHENYLALANINE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYMER; RAPAMYCIN; RECOMBINANT HUMAN INSULIN; RIFAMPICIN; TOBRAMYCIN; TRYPTOPHAN; VANCOMYCIN; VORICONAZOLE; EXCIPIENT;

BRONCHIECTASIS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRY POWDER INHALER; FREEZE DRYING; GRAFT REJECTION; HUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SPRAY DRYING; AEROSOL; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; POWDER;

ADMINISTRATION, INHALATION; AEROSOLS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; PARTICLE SIZE; POWDERS;

EID: 84955601372     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.01.002     Document Type: Review

References (141)

1. Gradon L., Sosnowski T.R. Formation of particles for dry powder inhalers. Adv. Powder Technol. 2014, 25:43-55.
2. Kurniawansyah F., Duong H.T.T., Danh L.T., Mammucari R., Vittorio O., Boyer C., Foster N. Inhalable curcumin formulations: micronization and bioassay. Chem. Eng. J. 2015, 279:799-808.
3. Leone-Bay A., Baughman R., Smutney C., Kocinsky J. Innovation in Drug Delivery by Inhalation 2010, 4-8. (http://www.ondrugdelivery.com).
4. Amaro M.I., Tewes F., Gob O., Tajber L., Corrigan O.I., Ehrhardt C., Healy A.M. Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. Int. J. Pharm. 2015, 483:6-18.
5. Depreter F., Amighi K. Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration. Eur. J. Pharm. Biopharm. 2010, 76:454-463.
6. Sato H., Ogawa K., Kojo Y., Kawabata Y., Mizumotob T., Yamada S., Onoue S. Development of cyclosporine A-loaded dry-emulsion formulation using highly purified glycerol monooleate for safe inhalation therapy. Int. J. Pharm. 2013, 448:282-289.
7. Zhang J., Wua L., Chan H.-K., Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv. Drug Deliv. Rev. 2011, 63:441-455.
8. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 2001, 48:27-42.
9. Chan H.-K. Formulation challenges: protein powders for inhalation. Modified-release Drug Delivery Technology 2008, vol. 2:631-643. Informa Healthcare, New York, Ch.47. second ed. R. MJ, J. Hadgraft, R. MS (Eds.).
10. Pilcer G., Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 2010, 392:1-19.
11. Depreter F., Pilcer G., Amighi K. Inhaled proteins: challenges and perspectives. Int. J. Pharm. 2013, 447:251-280.
12. Elversson J., Millqvist-Fureby A., Alderborn G., Elofsson U. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J. Pharm. Sci. 2003, 92:900-910.
13. Zhou Q., Leung S.S.Y., Tang P., Parumasivam T., Loh Z.H., Chan H.-K. Inhaled formulations and pulmonary drug delivery systems for respiratory infections. Adv. Drug Deliv. Rev. 2015, 85:83-99.
14. Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Technological and practical challenges of dry powder inhalers and formulations. Adv. Drug Deliv. Rev. 2014, 75:18-31.
15. Silva A.S., Tavares M.T., Aguiar-Ricardo A. Sustainable strategies for nano-in-micro particle engineering for pulmonary delivery. J. Nanoparticle Res. 2014, 16:1-17.
16. Laitinen R., Löbmann K., Grohganz H., Strachan C., Rades T. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability. Mol. Pharm. 2014, 11:2381-2389.
17. Rasenack N., Müller B.W. Micron-size drug particles: common and novel micronization techniques. Pharm. Dev. Technol. 2004, 9:1-13.
18. Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respir. Care 2005, 50:1209-1227.
19. Zijlstra G.S., Hinrichs W.L., de Boer A.H., Frijlink H.W. The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix. Eur. J. Pharm. Sci. 2004, 23:139-149.
20. Lizio R., Damm M., Sarlikiotis A.W., Bauer H.H., Lehr C.M. Low-temperature micronization of a peptide drug in fluid propellant: case study cetrorelix. AAPS PharmSciTech 2001, 2.
21. Onoue S., Sato H., Kawabata Y., Mizumoto T., Hashimoto N., Yamada S. In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy. J. Control. Release 2009, 138:16-23.
22. Onoue S., Sato H., Ogawa K., Kawabata Y., Mizumoto T., Yuminoki K., Hashimoto N., Yamada S. Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach. Int. J. Pharm. 2010, 399:94-101.
23. Lin Y.-W., Wong J., Qu L., Chan H.-K., Zhou Q.T. Powder production and particle engineering for dry powder inhaler formulations. Curr. Pharm. Des. 2015, 21:3902-3916.
24. Sou T., Kaminskas L.M., Nguyen T.H., Carlberg R., McIntosh M.P., Morton D.A.V. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur. J. Pharm. Biopharm. 2013, 83:234-243.
25. Sou T., McIntosh M.P., Kaminskas L.M., Prankerd R.J., Morton D.A.V. Designing a multicomponent spray-dried formulation platform for pulmonary delivery of biomacromolecules: the effect of polymers on the formation of an amorphous matrix for glassy state stabilization of biomacromolecules. Dry. Technol. 2013, 31:1451-1458.
26. Weers J.G., Tarara T.E., Clark A.R. Design of fine particles for pulmonary drug delivery. Expert Opin. Drug Deliv. 2007, 4(3):297-313.
27. Learoyd T.P., Burrows J.L., French E., Seville P.C. Sustained delivery by leucine-modified chitosan spray-dried respirable powders. Int. J. Pharm. 2009, 372:97-104.
28. Wan F., Maltesen M.J., Andersen S.K., Bjerregaard S., Foged C., Rantanen J., Yang M. One-step production of protein-loaded PLGA microparticles via spray drying using 3-fluid nozzle. Pharm. Res. 2014, 31:1967-1977.
29. Son Y.-J., McConville J.T. Preparation of sustained release rifampicin microparticles for inhalation. J. Pharm. Pharmacol. 2012, 64:1291-1302.
30. Ozeki T., Tagami T. Drug/polymer nanoparticles prepared using unique spray nozzles and recent progress of inhaled formulation. Asian J. Pharm. Sci. 2014, 9:236-243.
31. Capretto L., Carugo D., Mazzitelli S., Nastruzzi C., Zhang X. Microfluidic and lab-on-a-chip preparation routes for organic nanoparticles and vesicular systems for nanomedicine applications. Adv. Drug Deliv. Rev. 2013, 65:1496-1532.
32. Razavi Rohani S., Abnous K., Tafaghodi M. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients. Int. J. Pharm. 2014, 465:464-478.
33. Hoe S., Ivey J.W., Boraey M.A., Shamsaddini-Shahrbabak A., Javaheri E., Matinkhoo S., Finlay W.H., Vehring R. Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery. Pharm. Res. 2014, 31:449-465.
34. Chow A.H.L., Tong H.H.Y., Chattopadhyay P., Shekunov B.Y. Particle engineering for pulmonary drug delivery. Pharm. Res. 2007, 24:411-437.
35. Kawakami K., Sumitani C., Yoshihashic Y., Yonemochic E., Terada K. Investigation of the dynamic process during spray-drying to improve aerodynamic performance of inhalation particles. Int. J. Pharm. 2010, 390:250-259.
36. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm. Res. 2008, 25:999-1022.
37. Hoppentocht M., Hagedoorn P., Frijlink H.W., de Boer A.H. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation. Eur. J. Pharm. Biopharm. 2014, 86:23-30.
38. Schammé B., Couvrat N., Malpeli P., Delbreilh L., Dupray V., Dargent É., Coquerel G. Crystallization kinetics and molecular mobility of an amorphous active pharmaceutical ingredient: a case study with biclotymol. Int. J. Pharm. 2015, 490:248-257.
39. Chan H.-K., Chew N.Y.K. Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv. Drug Deliv. Rev. 2003, 55:793-805.
40. ®: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. 2005, 7:896-906.
41. Boraey M.A., Hoe S., Sharif H., Miller D.P., Lechuga-Ballesteros D., Vehring R. Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol-water cosolvent system. Powder Technol. 2013, 236:171-178.
42. Sebti T., Amighi K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur. J. Pharm. Biopharm. 2006, 63:51-58.
43. Amorij J.-P., Huckriede A., Wilschut J., Frijlink H.W., Hinrichs W.L.J. Development of stable influenza vaccine powder formulations: challenges and possibilities. Pharm. Res. 2008, 25:1256-1273.
44. Claus S., Schoenbrodt T., Weiler C., Friess W. Novel dry powder inhalation system based on dispersion of lyophilisates. Eur. J. Pharm. Sci. 2011, 43:32-40.
45. Yamashita C., Nishibayashi T., Akashi S., Toguchi H., Odomi M. A novel formulation of dry powder for inhalation of peptides and proteins. Respir. Drug Deliv. VI. 1998, 1:483-486.
46. D'Addio S.M., Chan J.G.Y., Kwok P.C.L., Prud'homme R.K., Chan H.-K. Constant size, variable density aerosol particles by ultrasonic spray freeze drying. Int. J. Pharm. 2012, 427:185-191.
47. Wanning S., Süverkrüp R., Lamprecht A. Pharmaceutical spray freeze drying. Int. J. Pharm. 2015, 488:136-153.
48. Wang Z.L., Finlay W.H., Peppler M.S., Sweeney L.G. Powder formation by atmospheric spray-freeze-drying. Powder Technol. 2006, 170:45-52.
49. Reverchon E. Supercritical antisolvent precipitation of micro- and nano-particles. J. Supercrit. Fluids 1999, 15:1-21.
50. Jovanović N., Bouchard A., Hofland G.W., Witkamp G.-J., Crommelin D.J.A., Jiskoot W. Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm. Res. 2004, 21:1955-1969.
51. Tandya A., Dehghani F., Foster N.R. Micronization of cyclosporine using dense gas techniques. J. Supercrit. Fluids 2006, 37:272-278.
52. Bustami R., Chan H.-K., Dehghani F., Foster N.R. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm. Res. 2000, 17:1360-1366.
53. Brough C., Williams R.O. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. Int. J. Pharm. 2013, 453:157-166.
54. Kawabata Y., Wada K., Nakatani M., Yamada S., Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int. J. Pharm. 2011, 420:1-10.
55. Laitinen R., Löbmann K., Strachan C.J., Grohganz H., Rades T. Emerging trends in the stabilization of amorphous drugs. Int. J. Pharm. 2013, 453:65-79.
56. Hellrup J., Mahlin D. Pharmaceutical micro-particles give amorphous sucrose higher physical stability. Int. J. Pharm. 2011, 409:96-103.
57. Weers J.G., Miller D.P. Formulation design of dry powders for inhalation. Int. J. Pharm. 2015, 104:3259-3288.
58. Schüle S., Schulz-Fademrecht T., Garidel P., Bechtold-Peters K., Frieß W. Stabilization of IgG1 in spray-dried powders for inhalation. Eur. J. Pharm. Biopharm. 2008, 69:793-807.
59. Claus S., Weiler C., Schiewe J., Friess W. Optimization of the fine particle fraction of a lyophilized lysozyme formulation for dry powder inhalation. Pharm. Res. 2013, 30:1698-1713.
60. Sou T., Orlando L., McIntosh M.P., Kaminskas L.M., Morton D.A.V. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int. J. Pharm. 2011, 421:220-229.
61. Cavaiola T.S., Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin. Ther. 2014, 36:1275-1289.
62. Healy A.M., Amaro M.I., Paluch K.J., Tajber L. Dry powders for oral inhalation free of lactose carrier particles. Adv. Drug Deliv. Rev. 2014, 75:32-52.
63. Sadrzadeh N., Miller D.P., Ballesteros D.L., Harper N.J., Stevenson C.L., Bennett D.B. Solid-state stability of spray-dried insulin powder for inhalation: chemical kinetics and structural relaxation modeling of Exubera above and below the glass transition temperature. J. Pharm. Sci. 2009, 99:3698-3710.
64. Ógáin O.N., Li J., Tajber L., Corrigan O.I., Healy A.M. Particle engineering of materials for oral inhalation by dry powder inhalers. I - particles of sugar excipients (trehalose and raffinose) for protein delivery. Int. J. Pharm. 2011, 405:23-35.
65. ® insulin pulmonary delivery system. Mucosal Delivery of Biopharmaceuticals 2014, 461-481. Springer Science Business Media, NewYork. J. Neves, B. Sarmento (Eds.).
66. ® (insulin human [rDNA origin]) inhalation powder an ultra-rapid acting insulin treatment to improve glycemic control in adult patients with diabetes mellitus, Briefing Document, Endocrinologic and Metabolic Drug Advisory Committee, FDA April 01 2014, (http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm390865.pdf accessed 12 Nov 2015).
67. ®: an inhalation system for pulmonary delivery of biopharmaceuticals. Mucosal Delivery of Biopharmaceuticals 2014, 483-498. Springer Science + Business Media, NewYork. J. Neves, B. Sarmento (Eds.).
68. Shen Z.G., Chen W.H., Jugade N., Gaob L.Y., Gloverb W., Shen J.Y., Yun J., Chen J.F. Fabrication of inhalable spore like pharmaceutical particles for deep lung deposition. Int. J. Pharm. 2012, 430:98-103.
69. Wu X., Zhang W., Hayes D., Mansour H.M. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. Int. J. Nanomedicine 2013, 8:1269-1283.
70. Onoue S. Strategic formulation study on dry powder inhalation system based on modulated molecular properties and controlled pharmacokinetics. J. Pharm. Soc. Jpn. 2013, 133:93-98.
71. Chiou H., Chan H.-K., Heng D., Prud'homme R.K., Raper J.A. A novel production method for inhalable cyclosporine A powders by confined liquid impinging jet precipitation. J. Aerosol Sci. 2008, 39:500-509.
72. Yamasaki K., Kwok P.C.L., Fukushige K., Prud'homme R.K., Chan H.-K. Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former. Int. J. Pharm. 2011, 420:34-42.
73. Adi S., Adi H., Chan H.-K., Tong Z., Yang R., Yu A. Effects of mechanical impaction on aerosol performance of particles with different surface roughness. Powder Technol. 2013, 236:164-170.
74. Chew N.Y.K., Chan H.-K. Use of solid corrugated particles to enhance powder aerosol performance. Pharm. Res. 2001, 18:1570-1577.
75. Wang Q., Guan Y.-X., Yao S.-J., Zhu Z.-Q. Controllable preparation and formation mechanism of BSA microparticles using supercritical assisted atomization with an enhanced mixer. J. Supercrit. Fluids 2011, 56:97-104.
76. Chan H.-K., Kwok P.C.L. Production methods for nanodrug particles using the bottom-up approach. Adv. Drug Deliv. Rev. 2011, 63:406-416.
77. Hoppentocht M., Akkerman O.W., Hagedoorn P., Frijlink H.W., de Boer A.H. The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™ family. Eur. J. Pharm. Biopharm. 2015, 90:8-15.
78. Geller D.E., Weers J., Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using pulmospheretm technology. J. Aerosol Med. Pulm. Drug Deliv. 2011, 24:175-183.
79. ® for persons with cystic fibrosis: a review. Med. Device Evid. Res. 2011, 4:179-188.
80. Miller D.P., Tan T., Tarara T.E., Nakamura J., Malcolmson R.J., Weers J.G. Physical characterization of tobramycin inhalation powder: I. Rational design of a stable engineered-particle formulation for delivery to the lungs. Mol. Pharm. 2015, 12:2582-2593.
81. Li X., Vogt F.G., Hayes D., Mansour H.M. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. Eur. J. Pharm. Sci. 2014, 52:191-205.
82. Park C.-W., Li X., Vogt F.G., Hayes D., Zwischenbergerf J.B., Park E.-S., Mansour H.M. Advanced spray-dried design, physicochemical characterization, andaerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. Int. J. Pharm. 2013, 455:374-392.
83. Carvalho S.R., Watts A.B., Peters J.I., Liu S., Hengsawas S., Escotet-Espinozae M.S., Williams R.O. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats. Eur. J. Pharm. Biopharm. 2014, 88:136-147.
84. Pilcer G., Rosière R., Traina K., Sebti T., Vanderbist F., Amighi K. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J. Pharm. Sci. 2013, 102:1836-1846.
85. Pilcer G., De Buegera V., Traina K., Traore H., Sebti T., Vanderbist F., Amighi K. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int. J. Pharm. 2013, 451:112-120.
86. Velkov T., Rahim N.A., Zhou Q.T., Chan H.-K., Li J. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead. Adv. Drug Deliv. Rev. 2015, 85:65-82.
87. Zhou Q., Morton D.A.V., Yu H.H., Jacob J., Wang J., Li J., Chan H.K. Colistin powders with high aersolization efficiency for respiratory infection: preparation Andin vitro evaluation. J. Pharm. Sci. 2013, 102:3736-3747.
88. Zhou Q., Gengenbach T., Denman J.A., Yu H.H., Li J., Chan H.-K. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. AAPS J. 2014, 16:37-47.
89. Wang W., Zhou Q.T., Sun S.-P., Denman J.A., Gengenbach T.R., Barraud N., Rice S.A., Li J., Yang M., Chan H.-K. Effects of surface composition on the aerosolisation and dissolution of inhaled antibiotic combination powders consisting of colistin and rifampicin. AAPS J. 2016, (in press).
90. Zhou Q., Sun S.-P., Chan J.G.Y., Wang P., Barraud N., Rice S.A., Wang J., Li J., Chan H.-K. Novel inhaled combination powder containing amorphous colistin and crystalline rifapentine with enhanced antimicrobial activities against planktonic cells and biofilm of Pseudomonas aeruginosa for respiratory infections. Mol. Pharm. 2015, 12:2594-2603.
91. Duddu S.P., Sisk S.A., Walter Y.H., Tarara T.E., Trimble K.R., Clark A.R., Eldon M.A., Elton R.C., Pickford M., Hirst P.H., Newman S.P., Weers J.G. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm. Res. 2002, 19:689-695.
92. Nolan L.M., Tajber L., McDonald B.F., Barham A.S., Corrigan O.I., Healy A.M. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery. Eur. J. Pharm. Sci. 2009, 37:593-602.
93. Tajber L., Corrigan D.O., Corrigan O.I., Healy A.M. Spray drying of budesonide, formoterol fumarate and their composites-I. Physicochemical characterization. Int. J. Pharm. 2009, 367:79-85.
94. Corrigan D.O., Corrigan O.I., Healy A.M. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int. J. Pharm. 2006, 322:22-30.
95. Yoshioka S., Aso Y. Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. Int. J. Pharm. 2007, 96:960-981.
96. Chang L., Shepherd D., Sun J., Ouellette D., Grant K.L., Tang X., Michael J.P. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?. J. Pharm. Sci. 2005, 94:1427-1444.
97. Chang L., Shepherd D., Sun J., Tang X., Michael J.P. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: implications for the mechanism of protein stabilization in the solid state. J. Pharm. Sci. 2005, 94:1445-1455.
98. Yoshioka S., Miyazaki T., Aso Y. β-Relaxation of insulin molecule in lyophilized formulations containing trehalose or dextran as a determinant of chemical reactivity. Pharm. Res. 2006, 23:961-966.
99. Tanaka K., Kitamura S., Kitagawa T. Effect of structural relaxation on the physical and aerosol properties of amorphous form of FK888 (NK1 antagonist). Chem. Pharm. Bull. 2005, 53:498-502.
100. Ajmera A., Scherließ R. Stabilisation of proteins via mixtures of amino acids during spray drying. Int. J. Pharm. 2014, 463:98-107.
101. Stigliani M., Aquino R.P., Gaudio P.D., Mencherini T., Sansone F., Russo P. Non-steroidal anti-inflammatory drug for pulmonary administration: design and investigation of ketoprofen lysinate fine dry powders. Int. J. Pharm. 2013, 448:198-204.
102. Raula J., Kurkela J.A., Brown D.P., Kauppinen E.I. Study of the dispersion behaviour of L-leucine containing microparticles synthesized with an aerosol flow reactor method. Powder Technol. 2007, 177:125-132.
103. Raula J., Thielmann F., Kansikas J., Hietala S., Annala M., Seppälä J., Lähde A., Kauppinen E.I. Investigations on the humidity-induced transformations of salbutamol sulphate particles coated with L-leucine. Pharm. Res. 2008, 25:2250-2261.
104. Wang L., Zhang Y., Tang X. Characterization of a new inhalable thymopentin formulation. Int. J. Pharm. 2009, 375:1-7.
105. Faghihi H., Vatanara A., Najafabadi A.R., Ramezani V., Gilani K. The use of amino acids to prepare physically and conformationally stable spray-dried IgG with enhanced aerosol performance. Int. J. Pharm. 2014, 466:163-171.
106. Mangal S., Meiser F., Tan G., Gengenbach T., Denman J., Rowles M.R., Larson I., Morton D.A.V. Relationship between surface concentration of L-leucine and bulk powder properties in spray dried formulations. Eur. J. Pharm. Biopharm. 2015, 94:160-169.
107. Lechuga-Ballesteros D., Charan C., Stults C.L.M., Stevenson C.L., Miller D.P., Vehring R., Tep V., Kuo M.C. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. Int. J. Pharm. Sci. Res. 2008, 97:287-302.
108. Kadota K., Nishimura T., Hotta D., Tozuka Y. Preparation of composite particles of hydrophilic or hydrophobic drugs with highly branched cyclic dextrin via spray drying for dry powder inhalers. Powder Technol. 2015, 283:16-23.
109. Parsian A.R., Vatanara A., Rahmati M.R., Gilani K., Khosravi K.M., Najafabadi A.R. Inhalable budesonide porous microparticles tailored by spray freeze drying technique. Powder Technol. 2014, 260:36-41.
110. Fabio K., Curley K., Guarneri J., Adamo B., Laurenzi B., Grant M., Offord R., Kraft K., Leone-Bay A. Heat-stable dry powder oxytocin formulations for delivery by oral inhalation. AAPS PharmSciTech 2015, 10.1208/s12249-015-0314-0.
111. Merchant Z., Taylor K.M.G., Stapleton P., Razak S.A., Kunda N., Alfagih I., Sheikh K., Saleem I.Y., Somavarapu S. Engineering hydrophobically modified chitosan for enhancing the dispersion of respirable microparticles of levofloxacin. Eur. J. Pharm. Biopharm. 2014, 88:816-829.
112. Gaspar M.C., Sousa J.J.S., Pais A.A.C.C., Cardoso O., Murtinho D., Serra M.E.S., Tewes F., Olivier J.-C. Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. Eur. J. Pharm. Biopharm. 2015, 96:65-75.
113. Osman R., Kan P.L., Awad G., Mortada N., EL-Shamy A.-E., Alpar O. Spray dried inhalable ciprofloxacin powder with improved aersolization and antimicrobial activity. Int. J. Pharm. 2013, 449:44-58.
114. Salama R., Hoe S., Chan H.-K., Traini D., Young P.M. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation. 1: influence of polymer concentration on physical and in vitro characteristics. Eur. J. Pharm. Biopharm. 2008, 69:486-495.
115. Beinborn N.A., Lirola H.L., Williams R.O. Effect of process variables on morphology and aerodynamic properties of voriconazole formulations produced by thin film freezing. Int. J. Pharm. 2012, 429:46-57.
116. Hasija M., Li L., Rahman N., Ausar S. Forced degradation studies: an essential tool for the formulation development of vaccines. Vaccine: Dev. Ther. 2013, 3:11-33.
117. Pham D.-D., Grégoire N., Couet W., Gueutin C., Fattal E., Tsapis N. Pulmonary delivery of pyrazinamide-loaded large porous particles. Eur. J. Pharm. Biopharm. 2015, 94:241-250.
118. Chew N.Y.K., Tang P., Chan H.-K., Raper J.A. How much particle surface corrugation is sufficient to improve aerosol performance of powders?. Pharm. Res. 2005, 22:148-152.
119. Feng A.L., Boraey M.A., Gwin M.A., Finlay P.R., Kuehl P.J., Vehring R. Mechanistic models facilitate efficient development of leucine containing microparticles for pulmonary drug delivery. Int. J. Pharm. 2011, 409:156-163.
120. Balducci A.G., Cagnani S., Sonvico F., Rossi A., Barata P., Colombo G., Colombo P., Buttini F. Pure insulin highly respirable powders for inhalation. Eur. J. Pharm. Sci. 2014, 51:110-117.
121. Duret C., Wauthoz N., Sebti T., Vanderbist F., Amighi K. Solid dispersions of itraconazole for inhalation with enhanced dissolution solubility and dispersion properties. Int. J. Pharm. 2012, 428:103-113.
122. Son Y.-J., Longest P.W., Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int. J. Pharm. 2013, 443:137-145.
123. Yoshinari T., Forbes R.T., York P., Kawashima Y. Moisture induced polymorphic transition of mannitol and its morphological transformation. Int. J. Pharm. 2002, 247:69-77.
124. Li X., Vogt F.G., Hayes D., Mansour H.M. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers. J. Pharm. Sci. 2014, 103:2937-2949.
125. Benhabiles M.S., Salah R., Lounici H., Drouiche N., Goosen M.F.A., Mameri N. Antibacterial activity of chitin, chitosan and its oligomers prepared from shrimp shell waste. Food Hydrocoll. 2012, 29:48-56.
126. Beinborn N.A., Du J., Wiederhold N.P., Smyth H.D.C., Williams R.O. Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice. Eur. J. Pharm. Biopharm. 2012, 81:600-608.
127. Cipolla D., Shekunov B., Blanchard J., Hickey A. Lipid-based carriers for pulmonary products: preclinical development and case studies in humans. Adv. Drug Deliv. Rev. 2014, 75:53-80.
128. Lu D., Hickey A.J. Liposomal dry powders as aerosols for pulmonary delivery of proteins. AAPS PharmSciTech 2005, 6:641-648.
129. Pilcer G., Sebti T., Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm. Res. 2006, 23:931-940.
130. Reddy S.C., Shivakumar H.G., Shyam M.M., Narendra C., Moin A. Karaya and ghatti gum as a novel polymer blend in preparation of extended release tablets: optimization by factorial design. J. Drug Delivery Sci. Technol. 2014, 24:525-532.
131. Chan J.G.Y., Chan H.-K., Prestidge C.A., Denman J.A., Young P.M., Traini D. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur. J. Pharm. Biopharm. 2013, 83:285-292.
132. Muhammad S.A.F.S., Langrish T., Tang P., Adi H., Chan H.-K., Kazarian S.G., Dehghani F. A novel method for the production of crystalline micronised particles. Int. J. Pharm. 2010, 388:114-122.
133. Moghaddam P.H., Ramezani V., Esfandi E., Vatanara A., Nabi-Meibodi M., Darabi M., Gilani K., Najafabadi A.R. Development of a nano-micro carrier system for sustained pulmonary delivery of clarithromycin. Powder Technol. 2013, 239:478-483.
134. Adi H., Young P.M., Chan H.-K., Agus H., Traini D. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Eur. J. Pharm. Sci. 2010, 40:239-247.
135. Tewes F., Paluch K.J., Tajber L., Gulati K., Kalantri D., Ehrhardt C., Healy A.M. Steroid/mucokinetic hybrid nanoporous microparticles for pulmonary drug delivery. Eur. J. Pharm. Biopharm. 2013, 85:604-613.
136. Amaro M.I., Tajber L., Corrigan O.I., Healy A.M. Optimisation of spray drying process conditions for sugar nanoporous microparticles (NPMPs) intended for inhalation. Int. J. Pharm. 2011, 421:99-109.
137. Tajber L., Corrigan O.I., Healy A.M. Spray drying of budesonide, formoterol fumarate and their composites-II. Statistical factorial design and in vitro deposition properties. Int. J. Pharm. 2009, 367:86-96.
138. Kho K., Hadinoto K. Dry powder inhaler delivery of amorphous drug nanoparticles: effects of the lactose carrier particle shape and size. Powder Technol. 2013, 233:303-311.
139. Arora S., Haghi M., Loo C.-Y., Traini D., Young P.M., Jain S. Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection. Mol. Pharm. 2015, 12:2001-2009.
140. Nolan L.M., Li J., Tajber L., Corrigan O.I., Healy A.M. Particle engineering of materials for oral inhalation by dry powder inhalers. II-sodium cromoglicate. Int. J. Pharm. 2011, 405:36-46.
141. Müller T., Krehl R., Schiewe J., Weiler C., Steckel H. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products. Eur. J. Pharm. Biopharm. 2015, 92:130-138.